… The current study examines the efficacy, safety, and tolerability of ASP8273 versus
erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR …

… The OS benefit from first-line treatment with dacomitinib versus gefitinib was maintained
after extended follow-up in patients with advanced NSCLC with EGFR-activating mutations. …

… -label, phase II, randomized controlled trial of erlotinib versus … therapy in patients with
stage IIIA-N2 non–small-cell lung … the superiority of adjuvant gefitinib over chemotherapy. The …

… in inhibiting mutant cell lines, including EGFR … to gefitinib and erlotinib [13]. Currently,
afatinib has been approved as a first-line treatment for patients with advanced non-small cell lung …

… et al; North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced
non–small-cell lung cancer harboring epidermal growth factor receptor mutations without …

… erlotinib and gefitinib had similar effectiveness but gefitinib had a better safety profile compared
to erlotinib… on the prevalence of patients taking erlotinib and gefitinib for treating NSCLC …

… were used to treat non-small cell lung cancer (NSCLC) patients with EGFR mutation positive…
TKIs; gefitinib, erlotinib, and afatinib in the treatment of advanced stage NSCLC patients with …

… six phase III trials, including four other trials using erlotinib or … EGFR-TKI gefitinib or erlotinib
for patients with metastatic … of postoperative adjuvant erlotinib/gefitinib for patients with …

… Non-small cell lung cancer (NSCLC) therapy DPs have been available in Poland since 1
July 2012. Initially, gefitinib was intended for 1 st line and erlotinib for 2 nd line patients. …

… G treatment versus gefitinib monotherapy in this study, the interaction effect for treatment and
TS expression level … factor receptor tyrosine kinase inhibitors in non–small cell lung cancer …